Presentations which confirm the leadership of
Gustave Roussy in the field of targeted therapies and immunotherapy
Gustave Roussy’s medical researchers will unveil their research work through 56 presentations at the congress of the American Society of Clinical Oncology (ASCO). The scientific committee of ASCO has selected 22 oral communications including 5 directly submitted by the Institute, 7 posters/discussions including 5 submitted by Gustave Roussy and 25 posters.
For this 51th edition of the most important world congress of cancer, Gustave Roussy confirmed its leadership in two therapeutic strategies which become daily supports and induce a change of the practices within the Oncological Medicine Department (OMD): the immunotherapy which develops in new pathologies as well as the targeted therapy and new approaches against the resistance that tumours may develop. This 2015 edition will be also marked by the early assessment of tomorrow’s therapies during phase I clinical trials, notably within the DITEP (Drug Development Department) of Gustave Roussy.
The main axes of Gustave Roussy's presentations:
- early phase and new drugs
- proof of concept in immunotherapy
- early phase and new medicinal products in paediatrics
- the development of targeted therapies in many pathologies
- female cancers
- the genito-urinary tumours
Learn more about Gustave Roussy's presentations: read the press release
